Kymera Therapeutics Presents New Preclinical Data for KT-579 Kymera Therapeutics, Inc. announced the presentation of new preclinical data for KT-579, a first-in-class, oral IRF5 degrader, …
In the Age of Ozempic: Accessibility and Cost The effectiveness and cost of weight loss drugs like Ozempic, Wegovy, and Mounjaro have been…
Designing Light-Filled Living Spaces In Florida, natural light is one of the state’s most abundant resources—and homeowners are increasing…
Isuzu FA Trophy Second Round Proper Draw Confirmed The draw for the Isuzu FA Trophy Second Round Proper has been announced, with 40 matche…
Navigating Complex Injury Cases Dealing with a serious injury case can be stressful and confusing, with nearly 70 percent of personal inju…
Dracula Technologies Secures €30M in Series A Round Valence, France-based Dracula Technologies has announced the successful completion of …
New Toronto Transit Station to Open A new station serving GO Transit's Kitchener Line and UP Express is set to open in weeks. Metro…
Rates of Physician Attrition From Clinical Practice Have Risen Since 2013 A recent study found that the rate of physician attrition from c…
Study Claims Ozempic Lowers Biological Age Researchers reveal that GLP-1 medication Ozempic may reduce biological age, offering new hope i…
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study Neumora Therapeutics, Inc. has initiated a Phase 1 single-ascending do…
World Treadmill Championships to Debut in 2026 The first-ever World Treadmill Championships, dubbed RUN X, will take place over 5km in 202…